v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]        
Service revenue $ 250,000 $ 250,000
Operating expenses:        
Research and development 345 297 1,140 594
General and administrative 1,093,220 65,672 2,945,810 166,472
Total operating expenses 1,093,565 65,969 2,946,950 167,066
Loss from operations (843,565) (65,969) (2,696,950) (167,066)
Other income (expense):        
Gain on derecognition of non-financial asset 1,100,000 1,100,000
Change in fair value equity investment 300,000 300,000
Interest expense, net (318,292) (207,780) (614,103) (411,579)
Change in fair value of derivative on debt 102,868 484,198 12,788 424,830
Total other income 1,184,576 276,418 798,685 13,251
Net income (loss) before non-controlling interests 341,011 210,449 (1,898,265) (153,815)
Net loss attributable to non-controlling interests (47,136) (67,407) (92,636) (132,955)
Net income (loss) attributable to Oncotelic Therapeutics, Inc. $ 388,147 $ 277,856 $ (1,805,629) $ (20,860)
Basic and diluted net income (loss) per share attributable to common stock $ 0.00 $ 0.00 $ (0.00) $ (0.00)
Basic and diluted weighted average common stock outstanding 447,386,505 408,292,720 445,596,158 407,860,290
Diluted net income (loss) per share attributable to common stock $ 0.00 $ 0.00 $ (0.00) $ (0.00)
Diluted weighted average common stock outstanding 467,914,165 452,809,058 445,596,158 407,860,290